FHD 909
Alternative Names: FHD-909; LY-4050784Latest Information Update: 16 Apr 2024
At a glance
- Originator Foghorn Therapeutics; Lilly Research Centre
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from the preclinical studies in Cancer released by Foghorn Therapeutics
- 11 Mar 2024 Foghorn Therapeutics has patent pending applications for "The present disclosure features compounds useful for the treatment of BAF complex-related disorders" in China, Japan, the European Union and multiple countries worldwide
- 08 Feb 2024 Lilly Research Centre announces intention to submit IND application for Non-small cell lung cancer in the second quarter of 2024